Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
The traditional Mediterranean diet has long been heralded as the gold standard for cardiovascular longevity, but a groundbreaking prospective study…
Read More
A collaborative research effort led by the Institute of Ion Beam Physics and Materials Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR)…
Read More
Centromeres, the vital chromosomal regions responsible for ensuring accurate cell division, exhibit a profound paradox: while their fundamental function is…
Read More
A comprehensive genomic study published in the journal Nature has fundamentally altered the scientific understanding of chronic myeloid leukemia (CML),…
Read More
Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…
Read More
For decades, the global scientific community has pursued the "holy grail" of energy: nuclear fusion. By replicating the processes that…
Read More
A groundbreaking discovery by a research team spearheaded by David Reverter, a scientist at the Universitat Autònoma de Barcelona (UAB),…
Read More
Acute Myelogenous Leukemia (AML) has long remained one of the most formidable challenges in oncology, characterized by its rapid progression…
Read More
In an era increasingly shaped by artificial intelligence, the promise of rapidly scalable, AI-driven enterprises has captivated the global imagination.…
Read More